Ret Fusion-Positive Thyroid Cancer

The FDA approved selpercatinib for the treatment of patients with one of three types of tumors that have RET alterations.

The FDA granted priority review to selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer, according to a press release from the agent’s manufacturer.